A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
Phase 2
Completed
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Drug: BI 1015550Drug: Placebo
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2022-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 147
- Registration Number
- NCT04419506
- Locations
- 🇨🇿
University Hospital Na Bulovce, Prague, Praha, Czechia
🇮🇹Azienda Ospedaliera Universitaria di Padova, Padova, Italy
🇮🇹A.O.U. Senese Policlinico Santa Maria alle Scotte, Siena, Italy
Tiotropium Plus Olodaterol vs Inhaled Corticosteroids (ICS) Regimens in the Portuguese Primary Care Setting (TIOLCOR Study)
Withdrawn
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: ICSDrug: TIO/OLO
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT04402515
A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 123
- Registration Number
- NCT04399837
- Locations
- 🇩🇪
Universitätsklinikum Bonn AöR, Bonn, Germany
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇩🇪Klinikum Oldenburg AöR, Oldenburg, Germany
A Trial in Healthy Chinese Volunteers to Test How Different Doses of BI 655130 Are Taken up in the Body
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Spesolimap
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 50
- Registration Number
- NCT04390568
- Locations
- 🇨🇳
Huashan Hospital, Fudan University, Shanghai, China
A Study to Test How Different Doses of BI 456906 Are Tolerated in Japanese Men With a Body Mass Index (BMI) Between 23 and 40 kg/m2
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BI 456906Drug: Placebo
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2021-01-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 37
- Registration Number
- NCT04384081
- Locations
- 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan
A Study to Test Long-term Treatment With Spesolimab in Patients With Fistulising Crohn's Disease Who Took Part in Previous Trials
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT04362254
- Locations
- 🇧🇪
Centre Hospitalier Universitaire de Liège, Liège, Belgium
🇳🇱Amsterdam UMC, Locatie AMC, Amsterdam, Netherlands
🇧🇪UZ Leuven, Leuven, Belgium
Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in Japan
- First Posted Date
- 2020-03-27
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 586
- Registration Number
- NCT04325217
- Locations
- 🇯🇵
Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan
TARA Working Prototype [Version 2]: Feasibility Study
Not Applicable
Withdrawn
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Device: Technology-Assisted Respimat Adherence Digital Behaviour Change Intervention
- First Posted Date
- 2020-03-25
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT04320524
A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2020-03-04
- Last Posted Date
- 2024-08-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24500
- Registration Number
- NCT04295005
- Locations
- 🇩🇪
Boehringer Ingelheim, Ingelheim am Rhein, Germany
Temporal Trends of Thrombolysis Treatment in Chinese Acute Ischemic Stroke (AIS) Patients From 2007-2017: Analysis of China National Stroke Registry (CNSR) I, II, and III; CTP-Draft Review Performed;
Completed
- Conditions
- Stroke
- Interventions
- Drug: IV rtPA (intravenous recombinant plasminogen activator)
- First Posted Date
- 2020-03-02
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 42188
- Registration Number
- NCT04290494
- Locations
- 🇨🇳
Beijing Tiantan Hospital, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath